Treatable traits in interstitial lung diseases: a call to action-Reference-Cited by-同舟云学术

Treatable traits in interstitial lung diseases: a call to action

Published:2023-02 Issue:2 Volume:11 Page:125-128
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Amati Francesco,Spagnolo Paolo,Oldham Justin M,Ryerson Christopher J,Stainer Anna,Gramegna Andrea,Mantero Marco,Lacedonia Donato,Sverzellati Nicola,Richeldi Luca,Blasi Francesco,Aliberti Stefano

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. Personalised medicine in interstitial lung diseases: number 6 in the Series “personalised medicine in respiratory diseases” edited by Renaud Louis and Nicolas Roche;Kokosi;Eur Respir Rev,2018

2. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease;Hoffmann-Vold;EBioMedicine,2019

3. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report;McDonald;Eur Respir J,2019

4. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype;Olson;Eur Respir Rev,2018

5. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline;Raghu;Am J Respir Crit Care Med,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases;Biomedicines;2024-05-09

2. Response to: are there over 200 distinct types of interstitial lung diseases?;Respiratory Research;2024-03-06

3. Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review;BMJ Open Respiratory Research;2024-03

4. Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis;Respiratory Research;2023-12-16

5. Treatable traits models of care;Respirology;2023-12-12